A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Carbamazepine (Carbamazepin)

INDICATIONS AND USAGE Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug.

First FDA approval1968-03-11
Generic availableYes · 21 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$188.3M in CY2024 Part D spend2.0M claims · 421K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.104/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.119
Across all dosage forms in distribution.
Highest NADAC
$0.123
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Carbamazepine used for?

INDICATIONS AND USAGE Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug.

Is there a generic for Carbamazepine?

Yes. 64 ANDAs filed at FDA, 21 generic manufacturers currently shipping.

How much does my plan pay for Carbamazepine?

Across 329 Part D plans, Carbamazepine averages $0.119/unit (NADAC). Lowest available: $0.104/unit. Highest in distribution: $0.123/unit.

Is Carbamazepine on the FDA shortage list?

Carbamazepine has been discontinued by its manufacturer(s).

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Mood Stabilizer2 alternatives in D1
01
Carbamazepine Er
Mood Stabilizer
$0.226Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Divalproex
Brand: Depakote
$0.055Lowest NADAC
21Generic mfrs
$362.1MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.